Search

Documents to discover everything about the latest progress in research for a given disease or group of diseases. See the publications in English. 

The impossible becomes possible! Thanks to the momentum of the Telethon and the work of researchers, a true scientific and medical revolution has begun and the first victories against rare diseases - previously incurable - have been won.  

Drugs in development or marketed with the support of AFM-Telethon concern neurological and neuromuscular diseases, diseases of the liver, vision, skin and immune system.

A look at clinical trials underway or in preparation in France and worldwide.

At each Telethon, thousands of volunteers and partners join forces to organize fundraising initiatives all over France and abroad. This participation is unique by its sheer scale.

Since 1987, the Telethon is a nearly thirty hours TV program broadcasted on the France Télévisions' channels. Discover all the ingrediants of the TV show.

Transparent and meticulous management: in 2023, AFM-Telethon committed €93.5 M to its social missions, in addition to €6.9 M in advances and investment for the Cure mission.  

Created in 1987 at the initiative of Bernard Barataud and Pierre Birambeau, both fathers of sons suffering grom Duchenne muscular dystrophy, the Telethon combines, since its first edition, a TV program and dozen of thousands of events throughout France. Discover the birth of this unique fundraising event.  

Treatments and therapeutic innovation are born out of the knowledge of genes and the understanding of the mechanisms causing disease. Beyond its three pioneering laboratories combined within the Biotherapies Institute for rare diseases, AFM-Telethon has been developing collaborations for many years with scientists from all over the world.

Committed to scientific research as well as to the support of patients and their families, AFM-Telethon acts independently, guided only by the urgency of the progressive disease, for the benefit of patients.  

AFM-Telethon wanted to formalise the objectives that clinical study protocols should pursue and the points of attention they call for concerning organisational and methodological aspects. This formalisation should help AFM members in their participation in protocols.

You are now on a website that is edited by the French Muscular Dystrophy Association (AFM-Téléthon), a 1901 law association of public utility. Its headquarters are based in Paris : AFM-Institut de Myologie, 47-83 boulevard de l’Hôpital, 75651 Paris Cedex 13.

AFM-Telethon has long struggled to defend the rights of patients, of people living with disabilities, and to obtain recognition for rare diseases. As a driver of research and innovation, it defends an ambitious national policy.  

The AFM-Telethon has chosen to implement a strategy of public interest to benefit as many people as possible.  

While the first gene therapy drugs are obtaining marketing authorization and being made available to patients, the challenge of industrializing their production is a crucial one.